Stockscreener 앱 받기
5.42
4.91%
-0.28
시장 영업 전:
5.64
0.22
+4.06%
Cadrenal Therapeutics Inc 주식(CVKD)의 최신 뉴스
Is Cadrenal Therapeutics Inc. stock a safe haven assetWeekly Trend Report & Smart Allocation Stock Tips - mfd.ru
Fed Meeting: Can Cadrenal Therapeutics Inc stock double in the next yearIndex Update & Free Safe Capital Growth Stock Tips - baoquankhu1.vn
Cadrenal Therapeutics (NASDAQ:CVKD) Shares Up 0.4% – What’s Next? - Defense World
(CVKD) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Profit Review: Will Cadrenal Therapeutics Inc outperform its industry peersMarket Risk Analysis & Daily Risk Controlled Trade Plans - baoquankhu1.vn
Update Recap: Will Cadrenal Therapeutics Inc outperform its industry peersJuly 2025 Opening Moves & Verified Momentum Stock Ideas - baoquankhu1.vn
Cadrenal Therapeutics expands at-the-market stock offering capacity - MSN
(CVKD) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Aug Momentum: Is Cadrenal Therapeutics Inc stock overvalued or fairly pricedMarket Volume Summary & Advanced Swing Trade Entry Plans - baoquankhu1.vn
Why is Cadrenal Therapeutics stock drawing retail attention today? - MSN
Cadrenal Advances Anticoagulation Pipeline, VLX-1005 Completes Phase 2 Trial - Intellectia AI
Why Is Cadrenal Therapeutics Stock Drawing Retail Attention Today? - Stocktwits
(CVKD) Risk Channels and Responsive Allocation - Stock Traders Daily
CVKD: VLX-1005 and Tecarfarin lead a strategy to address unmet needs in rare anticoagulation markets - TradingView — Track All Markets
CVKD: VLX-1005 and tecarfarin drive innovation in underserved anticoagulation markets, with key milestones ahead - TradingView — Track All Markets
Trend Report: Can GMGI stock double in the next yearJuly 2025 Trade Ideas & High Accuracy Investment Entry Signals - baoquankhu1.vn
Income Plays: Is Cadrenal Therapeutics Incs ROIC above industry averageEarnings Miss & Fast Moving Stock Watchlists - baoquankhu1.vn
Cadrenal highlights potential of 12-LOX inhibitor for blood disorder By Investing.com - Investing.com Nigeria
Cadrenal highlights potential of 12-LOX inhibitor for blood disorder - Investing.com
Cadrenal Therapeutics Highlights High Incidence of Thrombotic Complications in Heparin-Induced Thrombocytopenia (HIT) at the J.P. Morgan Healthcare Conference and VLX-1005 as a Potential Therapeutic Solution as the First and Only Selective 12-LOX In - GlobeNewswire
Cadrenal Therapeutics, Inc. - MSN
Will Cadrenal Therapeutics Inc. stock keep outperforming rivals2025 Key Highlights & Community Verified Watchlist Alerts - Улправда
Will Cadrenal Therapeutics Inc. stock benefit from commodity pricesWeekly Trend Summary & Real-Time Volume Trigger Notifications - Улправда
Can Cadrenal Therapeutics Inc. stock deliver consistent earnings growthMarket Performance Summary & Weekly Consistent Profit Watchlists - Улправда
What sentiment indicators say about Cadrenal Therapeutics Inc. stockMarket Growth Report & Weekly Market Pulse Updates - Улправда
Risk Analysis: Why Cadrenal Therapeutics Inc. stock remains undervaluedBreakout Watch & Daily Profit Maximizing Tips - ulpravda.ru
How Cadrenal Therapeutics Inc. stock trades during market volatilityJuly 2025 Institutional & Stepwise Trade Execution Plans - Улправда
Is Cadrenal Therapeutics Inc. stock a contrarian buyTrade Performance Summary & Step-by-Step Swing Trade Plans - Улправда
Cadrenal Therapeutics acquires VLX-1005 from Veralox - MSN
(CVKD) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Cadrenal Therapeutics, Inc. Common Stock (CVKD) Stock Forecast & Price Prediction 2026–2030 - CoinCodex
Matthew Szot Sells 9,933 Shares of Cadrenal Therapeutics (NASDAQ:CVKD) Stock - Defense World
Cadrenal's Pipeline Looks Less Like a Microcap and More Like an Emergency Response System - The Globe and Mail
How a small biotech is building an emergency anticoagulation plan - Stock Titan
Cadrenal Therapeutics announces new securities purchase agreement - MSN
Cadrenal Is Rebuilding the Parts of Anticoagulation Everyone Else Gave Up On - ACCESS Newswire
Inside the drug startup rebuilding blood thinners for medicine’s toughest cases - Stock Titan
(CVKD) Volatility Zones as Tactical Triggers - Stock Traders Daily
Cadrenal Therapeutics Expands At-The-Market Stock Offering Capacity - The Globe and Mail
Cadrenal Therapeutics Appoints Dr. Golden to Board - MSN
Cadrenal Therapeutics (NASDAQ:CVKD) & Biodexa Pharmaceuticals (NASDAQ:BDRX) Financial Analysis - Defense World
Downgrade Watch: Will Cadrenal Therapeutics Inc stock benefit from commodity pricesEarnings Beat & Detailed Earnings Play Alerts - moha.gov.vn
Is Cadrenal Therapeutics Inc. stock attractive for long term wealth buildingJuly 2025 Big Picture & Fast Gaining Stock Strategy Reports - ulpravda.ru
How Cadrenal Therapeutics Inc. stock performs in stagflation2025 Support & Resistance & Fast Entry High Yield Stock Tips - Улправда
Is Cadrenal Therapeutics Inc. stock recession proofWeekly Profit Recap & Capital Efficient Trading Techniques - Улправда
1.24%
0.19%
자본화:
|
볼륨(24시간):